Who to call at Edesa Biotech, and when

Fundz watches for the moments Edesa Biotech starts buying, and tells you who to reach.

An alert the day Edesa Biotech raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Edesa Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Edesa Biotech. With Fundz connected, it knows.

Watch Fundz in

See plan options

Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Edesa Biotech Enters Collaboration and License Agreement with Kyorin Pharmaceutical

Nov 09, 2026

Contract Type

licensing

MarkhamBiotechnologyTherapeuticsPharmaceuticalBiopharma

Description

On November 8, 2026, Edesa Biotech, Inc. entered into a Collaboration and License Agreement with Kyorin Pharmaceutical Co., Ltd. Under the agreement, Kyorin receives an exclusive, royalty-bearing license to develop and commercialize Edesa's anti-TLR4 monoclonal antibody for treatment in Japan. Edesa will receive upfront payments and potential milestone payments, while retaining rights outside Japan and handling manufacturing.

Company Information

Company

Edesa Biotech

Location

100 SPY COURT

Markham, Ontario, Canada

About

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.